Loading
A phase 1/2 trial of tislelizumab, capecitabine and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Fudan University, now recruiting.
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy is a phase 1/2, interventional study registered as NCT07561060 by Fudan University, with a registry enrolment figure of 50 participants, started 2024-01-01 and due to reach its primary completion in 2027-12. Interventions recorded: Tislelizumab; Capecitabine; Oxaliplatin; Capecitabine. Conditions listed: Rectal Cancer. Primary outcome: Complete Response rate (CR rate). Colorectal eligibility wording from the registry: "Histologically confirmed rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.
Shares Tislelizumab, FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Tislelizumab, FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Tislelizumab, FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Tislelizumab, FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Tislelizumab, FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Tislelizumab, Capecitabine, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.